Evidence map›Paper›PMID 41362479›Full record

ArticleClinical and translational radiation oncology2026

Peng Zeng, Yong Wang, Duo Shen, Tiancheng Zhao, Rong Chen, Jinhe Guo, Haidong Zhu, Gao-Jun Teng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peng ZengDepartment of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.
Yong WangCenter of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.
Duo ShenDepartment of Gastroenterology, The Second People's Hospital of Changzhou, Nanjing Medical University, Changzhou, Jiangsu, China.
Tiancheng ZhaoDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Rong ChenDepartment of Radiotherapy, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.
Jinhe GuoCenter of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.
Haidong ZhuCenter of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.
Gao-Jun TengCenter of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Hepatocellular carcinoma (HCC) exhibits a complex immunosuppressive network, leading to resistance to immune checkpoint inhibitors (ICIs). To counter this, we introduced a novel method, brachytherapy of Methods and materials: Mouse orthotopic and subcutaneous HCC models were constructed with H22 cells. Results: Conclusions: Our brachy-primed immunotherapy approach offers a promising and effective treatment strategy, which may improve the immunotherapeutic efficacy in HCC.

Indexed as

125I seed brachytherapyHepatocellular carcinomaImmunomodulationImmunotherapyPD-1 inhibitor

Identifiers

PMID41362479
PMCPMC12681645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.